Research programme: biotin carboxylase inhibitor - PfizerAlternative Names: PD-0162819; PD-162819
Latest Information Update: 16 Jul 2016
At a glance
- Originator Pfizer
- Mechanism of Action Carbon nitrogen ligase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in USA
- 15 Sep 2009 Early research in Bacterial infections in USA (unspecified route)